218 related articles for article (PubMed ID: 24729617)
1. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
3. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
4. Detection of Complement Factor B Autoantibodies by ELISA.
Józsi M; Uzonyi B
Methods Mol Biol; 2021; 2227():141-145. PubMed ID: 33847939
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
Tanuma Y; Ohi H; Hatano M
Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
9. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
10. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
12. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
14. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
15. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
16. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.
Halbwachs L; Leveillé M; Lesavre P; Wattel S; Leibowitch J
J Clin Invest; 1980 Jun; 65(6):1249-56. PubMed ID: 6902727
[TBL] [Abstract][Full Text] [Related]
17. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
18. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
19. CRIT peptide interacts with factor B and interferes with alternative pathway activation.
Hui KM; Magnadóttir B; Schifferli JA; Inal JM
Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177
[TBL] [Abstract][Full Text] [Related]
20. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
Mold C; Medof ME
Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
